KROS
Keros Therapeutics, Inc.
Key Financials
Net Income
$87.0M
↑ 146.4%
Operating Income
$67.6M
↑ 132.0%
EPS (Diluted)
$2.30
↑ 146.0%
Total Assets
$338.0M
↓ 45.1%
Revenue
$243.9M
↑ Infinity%
Total Liabilities
$34.9M
↓ 21.3%
Cash & Equivalents
$287.4M
↓ 48.7%
Operating Cash Flow
$107.5M
↑ 166.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 8/18/2026 | View on SEC |
| 3 | 8/13/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 10-Q | 8/3/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| SCHEDULE 13G/A | 7/29/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| SCHEDULE 13G | 7/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KROS |
| Company Name | Keros Therapeutics, Inc. |
| CIK | 1664710 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 617-314-6297 |